indomethacin has been researched along with Abdominal Pain in 11 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To elucidate the effects of somatostatin and indomethacin mono or in combination to prevent hyperamylasemia and PEP in high-risk individuals." | 9.69 | Effects of Somatostatin and Indomethacin Mono or Combination Therapy on High-risk Hyperamylasemia and Post-pancreatitis Endoscopic Retrograde Cholangiopancreatography Patients: A Randomized Study. ( Qiu, P; Tan, S; Wang, G; Wu, Z; Xiao, G; Xiong, L, 2023) |
| "Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials." | 9.22 | Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. ( Bensen, SP; Fadden, LL; Gardner, TB; Gordon, SR; Hyder, SM; Lacy, BE; Levenick, JM; Levy, LC; Parr, DD; Rockacy, MJ, 2016) |
| "Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile." | 9.12 | Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. ( Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE, 2007) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 6.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| "To elucidate the effects of somatostatin and indomethacin mono or in combination to prevent hyperamylasemia and PEP in high-risk individuals." | 5.69 | Effects of Somatostatin and Indomethacin Mono or Combination Therapy on High-risk Hyperamylasemia and Post-pancreatitis Endoscopic Retrograde Cholangiopancreatography Patients: A Randomized Study. ( Qiu, P; Tan, S; Wang, G; Wu, Z; Xiao, G; Xiong, L, 2023) |
| "Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials." | 5.22 | Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. ( Bensen, SP; Fadden, LL; Gardner, TB; Gordon, SR; Hyder, SM; Lacy, BE; Levenick, JM; Levy, LC; Parr, DD; Rockacy, MJ, 2016) |
| "Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile." | 5.12 | Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. ( Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE, 2007) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 2.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| " during concomitant twice daily dosing with 400 micrograms misoprostol, 150 mg ranitidine or placebo." | 2.67 | Co-administration of misoprostol or ranitidine with indomethacin: effects on pharmacokinetics, abdominal symptoms and bowel habit. ( Gibson, R; Kendall, MJ; Walt, RP, 1992) |
| "BACKGROUND The aim of this study was to explore the risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and investigate the effect of octreotide combined with nonsteroidal anti-inflammatory drugs on preventing its occurrence." | 1.48 | Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis and the Effect of Octreotide Combined with Nonsteroidal Anti-Inflammatory Drugs on Preventing Its Occurrence. ( Shen, Y; Wang, J; Wu, S; Zheng, L; Zhong, Z, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gökçe, M | 1 |
| Utku, S | 1 |
| Küpeli, E | 1 |
| Wu, Z | 1 |
| Xiao, G | 1 |
| Wang, G | 1 |
| Xiong, L | 1 |
| Qiu, P | 1 |
| Tan, S | 1 |
| Wang, J | 1 |
| Shen, Y | 1 |
| Zhong, Z | 1 |
| Wu, S | 1 |
| Zheng, L | 1 |
| Singh, M | 1 |
| Reichert, P | 1 |
| Cann, H | 1 |
| Levenick, JM | 1 |
| Gordon, SR | 1 |
| Fadden, LL | 1 |
| Levy, LC | 1 |
| Rockacy, MJ | 1 |
| Hyder, SM | 1 |
| Lacy, BE | 1 |
| Bensen, SP | 1 |
| Parr, DD | 1 |
| Gardner, TB | 1 |
| Kocheril, SV | 1 |
| Blaivas, M | 1 |
| Appleton, BE | 1 |
| McCune, WJ | 1 |
| Ike, RW | 1 |
| Man, CY | 1 |
| Cheung, IT | 1 |
| Cameron, PA | 1 |
| Rainer, TH | 1 |
| Willburger, RE | 1 |
| Mysler, E | 1 |
| Derbot, J | 1 |
| Jung, T | 1 |
| Thurston, H | 1 |
| Kreiss, A | 1 |
| Litschig, S | 1 |
| Krammer, G | 1 |
| Tate, GA | 1 |
| Morgan, TO | 1 |
| Anderson, A | 1 |
| Bertram, D | 1 |
| Forshaw, MJ | 1 |
| Zayyan, K | 1 |
| Power, DM | 1 |
| Kendall, MJ | 1 |
| Gibson, R | 1 |
| Walt, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis[NCT03708458] | Phase 4 | 250 participants (Anticipated) | Interventional | 2017-04-01 | Recruiting | ||
| Rectal Indomethacin to Prevent Post-ERCP Pancreatitis[NCT01774604] | Phase 3 | 449 participants (Actual) | Interventional | 2013-01-31 | Terminated (stopped due to Futility) | ||
| A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis[NCT05252754] | Phase 3 | 4,874 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who died from any cause from the time of ERCP until 30 days post-procedure (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 0 |
| Placebo | 3 |
Number of patients who developed pancreatitis following ERCP based on Atlanta Classification (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 16 |
| Placebo | 11 |
Number of patients who developed any type of gastrointestinal bleeding from time of ERCP to 30 days post procedure (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 4 |
| Placebo | 6 |
Number of patient who developed mild acute pancreatitis based on the Atlanta Classification (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 16 |
| Placebo | 9 |
Number of patients with moderately severe pancreatitis based on Atlanta Classification (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 0 |
| Placebo | 1 |
Number of patients with severe acute pancreatitis based on the Atlanta Classification (NCT01774604)
Timeframe: From randomization to 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 0 |
| Placebo | 1 |
Number of patients admitted to the hospital for any cause following ERCP (NCT01774604)
Timeframe: From randomization until 30 days after ERCP
| Intervention | participants (Number) |
|---|---|
| Indomethacin | 31 |
| Placebo | 20 |
6 trials available for indomethacin and Abdominal Pain
| Article | Year |
|---|---|
Effects of Somatostatin and Indomethacin Mono or Combination Therapy on High-risk Hyperamylasemia and Post-pancreatitis Endoscopic Retrograde Cholangiopancreatography Patients: A Randomized Study.
Topics: Abdominal Pain; Cholangiopancreatography, Endoscopic Retrograde; Humans; Hyperamylasemia; Indomethac | 2023 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Topics: Abdominal Pain; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholang | 2016 |
Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.
Topics: Abdominal Pain; Acetaminophen; Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Analges | 2007 |
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Topics: Abdominal Pain; Acute Disease; Administration, Oral; Adult; Aged; Analysis of Variance; Argentina; D | 2007 |
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; | 2000 |
Co-administration of misoprostol or ranitidine with indomethacin: effects on pharmacokinetics, abdominal symptoms and bowel habit.
Topics: Abdominal Pain; Adolescent; Adult; Defecation; Digestive System; Drug Interactions; Feces; Humans; I | 1992 |
5 other studies available for indomethacin and Abdominal Pain
| Article | Year |
|---|---|
Synthesis and analgesic and anti-inflammatory activities 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(p-substituted/nonsubstituted benzal)hydrazone derivatives.
Topics: Abdominal Pain; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Edema; Hydrazones; Inf | 2009 |
Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis and the Effect of Octreotide Combined with Nonsteroidal Anti-Inflammatory Drugs on Preventing Its Occurrence.
Topics: Abdominal Pain; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroidal; China; Cholangiopanc | 2018 |
Abrupt onset of abdominal pain. Duodenal perforation caused by indomethacin.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Diseases; Humans; Indomethacin; In | 2013 |
Degos' disease mimicking vasculitis.
Topics: Abdominal Pain; Diagnosis, Differential; Dipyridamole; Drug Administration Schedule; Fatal Outcome; | 2004 |
NSAID-induced small bowel perforation.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Hip Fractures; Humans; Ileal Diseases; Indo | 2001 |